Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Jennings

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer GroupJ Russell Geyer, Richard Sposto, Mark Jennings, et al.
Annals of the American Thoracic Society|March 16, 2026
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension studyJames F Chmiel, Kimberly McBennett, Bradley S Quon, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Extension StudyCori L Daines, Deepika Polineni, Elizabeth Tullis, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled StudyMarcus A Mall, Rossa Brugha, Silvia Gartner, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 2, 2026
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosisEva Van Braeckel, Andrew T Braun, Nicholas J Simmonds, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer GroupJ Russell Geyer, Richard Sposto, Mark Jennings, et al.
Annals of the American Thoracic Society|March 16, 2026
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension studyJames F Chmiel, Kimberly McBennett, Bradley S Quon, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Extension StudyCori L Daines, Deepika Polineni, Elizabeth Tullis, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled StudyMarcus A Mall, Rossa Brugha, Silvia Gartner, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 2, 2026
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosisEva Van Braeckel, Andrew T Braun, Nicholas J Simmonds, et al.
Pageof 3